 SHANGHAI and GAITHERSBURG, Md., June 25, 2021 PRNewswire -- I-Mab the Company NASDAQ: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation CDE of the China National Medical Products Administration NMPA has approved the Investigational New Drug IND application to initiate a phase 1b trial of felzartamab, a CD38 antibody, in patients with systemic lupus erythematosus SLE. 